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Dynamic Regulation of T Cell Immunity by CD431
Thandi M. Onami,* Laurie E. Harrington,* Matthew A. Williams, † Marisa Galvan,§
Christian P. Larsen,† Thomas C. Pearson,† N. Manjunath,¶ Linda G. Baum,§ Brad D. Pearce,‡
and Rafi Ahmed2*
During a viral response, Ag-specific effector T cells show dramatically increased binding by the mAb 1B11 and the lectin peanut
agglutinin (PNA). We investigated the contribution of CD43 expression to 1B11 and PNA binding as well as its role in generation
and maintenance of a CD8 T cell response. Analysis of CD43/ mice revealed no increased 1B11 binding and reduced PNA
binding on virus-specific CD8 T cells from/ mice compared with / mice. Furthermore, we examined the role of CD43 in
the kinetics of an immune response. We show that CD43 expression modestly effects generation of a primary virus-specific CD8
T cell response in vivo but plays a more significant role in trafficking of CD8 T cells to tissues such as the brain. More interestingly,
CD43 plays a role in the contraction of the immune response, with CD43/ mice showing increased numbers of Ag-specific CD8
T cells following initial expansion. Following the peak of expansion, Ag-specific CD8 T cells from/ mice show similar pro-
liferation but demonstrate increased Bcl-2 levels and decreased apoptosis of Ag-specific effector CD8 T cells in vitro. Consistent
with a delay in the down-modulation of the immune response, following chronic viral infection CD43/ mice show increased
morbidity. These data suggest a dynamic role of CD43 during an immune response: a positive regulatory role in costimulation and
trafficking of T cells to the CNS and a negative regulatory role in the down-modulation of an immune response.The Journal of
Immunology, 2002, 168: 6022–6031.
T cells can be classified into three separate classes: naive,effector, and memory. During an immune response, Tcells are dramatically modified by both protein expression
and protein modification. We can generate and directly visualize
Ag-specific CD8 T cells at various times after lymphocytic cho-
riomeningitis virus (LCMV)3 infection using MHC class I tetram-
ers (1). Using this model, we have demonstrated that there are
changes in the glycosylation patterns of T cells in vivo following
viral infection based on binding to peanut agglutinin (PNA), dis-
tinguishing naive from activated T cells (2). Additionally, we have
recently shown that one surface marker, 1B11, can be used to
distinguish between memory and effector T cells (3). 1B11 binding
is low on CD8 naive cells and high on Ag-specific CD8 effector T
cells, and becomes reduced again on Ag-specific CD8 memory T
cells (3).
The abundant T cell surface glycoprotein CD43 (sialophorin,
gp115, leukosialin) is a transmembrane protein consisting of a
highly O-glycosylated extracellular domain of 235 amino acids, a
transmembrane domain of 23 amino acids, and an intracytoplasmic
domain of 123 amino acids (4). Posttranslational modifications
result in two glycoforms of CD43. The mAb S7 recognizes the
lower-molecular mass (115 kDa) glycoform (5), while the mAb
1B11 was initially characterized as recognizing the activation-as-
sociated, high-molecular mass (130 kDa) glycoform of CD43 (5).
This high-molecular mass glycoform bears core 2 O-glycans, an
oligosaccharide structure that can be created by the action of the
core 2 -1–6-N-acetylglucosaminyltransferase (6). Recently, one
report has shown that 1B11 recognizes a novel CD8 T cell-re-
stricted CD45RB epitope that is independent of core 2 O-glycans
on naive CD8 T cells (7). Thus, it was unclear which glycopro-
tein(s) 1B11 was binding on activated Ag-specific CD8 T cells.
Although CD43 is one of the most abundant T cell surface gly-
coproteins, its functions remain controversial. It has been pur-
ported to have antiadhesive as well as proadhesive functions in T
cell trafficking (8–11). Additionally, CD43 has been shown to play
a role in T cell activation, although this, too, remains unclear. Ab
cross-linking experiments suggested a costimulatory role in vitro
(12); however, other groups suggested a negative regulatory role in
T cell activation (8, 13). Most recently, it has been shown that
CD43 is excluded from the immunological synapse during T cell
activation, and this exclusion appears to be mediated by an ezrin-
radixin-moesin-dependent mechanism(s) (14–17).
To understand the role of CD43 on effector CD8 T cells during
an immune response, we generated Ag-specific effector CD8 T
cells in CD43-deficient mice. Surprisingly, there was a complete
absence of the up-regulation of 1B11 binding on these cells, firmly
establishing that the up-regulated binding of 1B11 observed on
effector CD8 T cells in vivo requires the expression of CD43. We
examined the course of a viral immune response in CD43/ mice
and found that while CD43 plays a positive regulatory role in the
costimulation and trafficking of naive T cells in vivo, it appears to
play a negative regulatory role in the waning/down-modulation of
effector T cell responses. These results suggest a dynamic role of
CD43 during an immune response that is reflective of its dynamic
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CD43/ mice and B6.129 control mice (CD43/) were purchased from
The Jackson Laboratory (Bar Harbor, ME) and bred in-house under spe-
cific pathogen-free conditions. For acute LCMV responses, naive adult
mice (5 wk) were infected with 2  105 PFU of LCMV-Armstrong i.p.
For LCMV disease studies, adult mice (4–6 wk old) were infected with
1  102 or 1  105 PFU LCMV-Armstrong intracranially (i.c.). For
chronic studies, adult mice (5 wk old) were infected with 2  106 PFU
LCMV clone 13 i.v.
Surface/tetramer staining, flow cytometry, and direct ex vivo
CTL assay
Spleens were harvested from mice and passed through a screen in 10%
FCS in RPMI with antibiotics and 2-ME. RBCs were lysed and cells were
washed and counted for total cell yields. For immunostaining, 1  106 cells
were stained in 96-well U-bottom plates. All mAbs and apoptosis reagents
(anti-CD8-PE, anti-CD62L-FITC, anti-CD44-FITC, S7-FITC, S7-PE,
1B11-FITC, anti-Bcl-2-FITC, anti-bromodeoxyuridine (BrdU)-FITC, An-
nexin V-FITC, and 7-amino actinomycin D (7-AAD)) were purchased
from BD PharMingen (San Diego, CA.) Production of MHC class I tet-
ramers DbNP396–404 and D
bgp33–41-allophycocyanin were done as pre-
viously described (1). PNA-FITC was purchased from Sigma-Aldrich (St.
Louis, MO). Flow cytometry was performed on a FACSCalibur (BD Bio-
sciences, Mountain View, CA). LCMV-specific CTL activity was deter-
mined by a 5-h 51Cr release assay as previously described (1).
Immunohistochemistry
CD8 T cell infiltrates in the brain were assessed by immunohistochemistry.
Brains were harvested from mice and cut in half. One half was used to
isolate CNS mononuclear cells and the other half was quick-frozen and
stored at 70°C until sectioned on a cryostat. Sagittal brain sections were
prepared from frozen tissue, ethanol-fixed for 20 min, transferred to PBS,
incubated with DAKO block (DAKO, Carpinteria, CA) for 45 min to block
endogenous peroxidase, followed by a 15-min block with 5% rabbit serum
in PBS, and stained with anti-CD8 and anti-CD8 Abs (BD PharMingen)
for 90 min. Sections were washed with PBS, incubated for 45 min with
biotinylated rabbit anti-rat Ab (Jackson ImmunoResearch Laboratories,
West Grove, PA), and developed with the ABC Elite kit (Vector Labora-
tories, Burlingame, CA) and DAB. Sections were counterstained with
Mayer’s hematoxylin. Images were analyzed using 4 and 20 objectives
and captured by digital photomicroscopy for final output.
Isolation of CNS mononuclear cells
Brain tissue was harvested from mice in 1% FCS in RPMI, transferred to
an ice-cold 7-ml Tenebroeck glass homogenizer in 5 ml medium, and ho-
mogenized to a smooth consistency. Brain homogenates were transferred to
conical tubes on ice and adjusted to a 7-ml volume, and 3 ml Percoll
(Sigma-Aldrich) was added to yield a final 30% Percoll concentration. This
was underlayed with 70% Percoll and centrifuged at 2500 rpm. The inter-
face was removed and washed, RBCs were lysed, and cells were stained
with anti-CD8 and MHC class I tetramers DbNP396–404 and D
bgp33–41.
IFN- ELISPOT assays
Allospecific T cell responses were measured by IFN- ELISPOT assay
using splenocytes or Histopaque separated (Sigma-Aldrich) peripheral
blood leukocytes obtained from skin-grafted CD43/ or CD43/ mice.
The capture Ab for this assay, rat anti-mouse IFN- (clone R4-6A2; BD
PharMingen), was incubated at 4 g/ml in PBS (100 l/well) at 4°C over-
night in ester cellulose-bottom 96-well plates (Millipore, Bedford, MA).
After washing with PBS, 3-fold serial dilutions of responding cells were
added. A total of 5  105 irradiated donor splenocytes (BALB/c) were
added to each well and plates were incubated overnight at 37°C. After the
culture period, cells were removed by washing the plates with PBS-Tween
(0.05%). Biotinylated anti-mouse IFN- (clone XMG1.2; BD PharMingen)
was added at 4 g/ml (100 l/well) for 2 h, plates were washed, and
HRP-avidin D (Vector Laboratories) was added for 1 h. Following a final
wash, spots were developed with the substrate 3-amino-9-ethyl-carbazole
(Sigma-Aldrich) with 0.015% H2O2, allowed to air dry, and quantitated.
BrdU incorporation
Mice were fed BrdU (Sigma-Aldrich) at 1 mg/ml in their drinking water,
changed daily, for days 8–15 following LCMV-Armstrong challenge i.p.
On day 15 mice were sacrificed and peripheral blood and spleen
were harvested. After perfusion with 5 ml cold PBS, liver was harvested.
PBMCs were isolated as previously described (1). Lymphocytes from the
liver were obtained after passage through a mesh screen. Cell suspensions
were incubated at 37°C for 1 h with a 10 stock of 2.5 mg/ml collagenase
B and 0.29 mg/ml DNase I in PBS. Large tissue debris was discarded and
cells were resuspended in 44% Percoll, underlayed with 56% Percoll, and
spun for 20 min at 2000 rpm in an IEC centrifuge (IEC, Needham Heights,
MA). After isolation from the Percoll gradient, RBCs were lysed and cell
yield was determined. Cell surface staining with MHC class I tetramers
specific for DbNP396–404 and anti-CD8-PE followed by intracellular stain-
ing for BrdU incorporation as per the manufacturer’s instructions (BrdU
Flow kit; BD PharMingen). Briefly, cells were permeabilized with Cytofix/
Cytoperm and treated with DNase to expose incorporated BrdU, followed
by staining with anti-BrdU-FITC.
In vitro apoptosis assay
Splenocytes were harvested from infected mice on days 8, 10, or 12 and
1  106 cells were cultured for 16 h in 96-well flat-bottom plates at 37°C.
Cells were transferred to a 96-well U-bottom plate for staining. Following
surface staining with MHC class I tetramers and anti-CD8 Abs, cells were
washed and incubated with annexin V staining buffer (10 mM HEPES/
NaOH (pH 7.4), 140 mM NaCl, 2.5 mM CaCl2) with a 1/20 dilution of
annexin V-FITC and a 1/5 dilution of 7-AAD (BD PharMingen) for 15 min
at room temperature. Cells were washed and immediately assayed by flow
cytometry.
Results
CD43-deficient mice generate Ag-specific effector CD8 T cells
CD43-deficient mice show normal T and B cell development and
have similar numbers of T lymphocytes in the periphery (8, 18).
Wild-type or CD43-deficient mice were infected i.p. with 2  105
PFU of the Armstrong strain of LCMV, and mice were sacrificed
8 or 65 days postinfection. Splenocytes and lymph node T cells
were stained with Abs to CD8, S7, or 1B11 and MHC class I
tetramers specific for the dominant epitopes Dbgp33–41 or
DbNP396–404 (1). Data from spleen cells are shown, but similar
results were obtained from lymph node cells. Similar percentages
of Ag-specific CD8 T cells were obtained from both genotypes
(Fig. 1A).
To analyze binding of mAbs S7 and 1B11, effector and memory
cells were gated for expression of CD8 and DbNP396–404 while
naive cells were gated on total CD8 T cells from uninfected mice.
As previously reported, CD43/ CD8 T cells do not express the
low molecular glycoform of CD43 as measured by the mAb S7 (8),
while CD43/ CD8 T cells express CD43 constitutively on na-
ive, effector, and memory CD8 T cells (Fig. 1B). However, binding
by 1B11 changes dramatically in CD43/ mice; 1B11 binding is
low on naive CD8 T cells, dramatically increased on virus-specific
effector CD8 T cells, and reduced on virus-specific memory CD8
T cells (Fig. 1B). Double staining of / effector CD8 T cells
with 1B11 and S7 reveals binding of both Abs on the same cells.
Binding by mAbs S7 and 1B11 on T cells from wild-type mice is
summarized in Table I.
We saw no evidence of increased 1B11 binding on / virus-
specific effector CD8 T cells, in marked contrast to / cells (Fig.
1B). Other surface markers such as CD44 and L-selectin were
unaffected and similar surface expression was observed between
/ and / effector CD8 T cells (Ref. 9 and data not shown).
These data demonstrate that the increased 1B11 binding on CD8
effector T cells requires the expression of CD43.
6023The Journal of Immunology











Reduced binding of PNA on effector and memory T cells in
CD43/ mice
We have previously demonstrated that virus-specific T cells be-
come PNAhigh, and this increased PNA reactivity may result from
increased neuraminidase activity in activated T cells (2). Alter-
ations in expression or activity of one or more sialyltransferases
could also affect PNA binding (19, 20). We examined PNA bind-
ing on T cells derived from CD43/ mice after challenge with
LCMV. Effector and memory cells were gated for expression of
CD8 and DbNP396–404, while naive cells were gated on CD44
low
CD8 T cells from uninfected mice. While PNA binding to effector
T cells was markedly up-regulated compared with naive cells from
both / and / mice, the level of binding to effector and
memory / CD8 T cells was significantly reduced compared
with similar populations of / cells (30–40%) (Fig. 1C).
While prior work has demonstrated that CD43 is a PNA-binding
glycoprotein on thymocytes (21), the data presented in this work
demonstrate that CD43 expression contributes to PNA binding by
activated peripheral T cells. This suggests that the glycosylation
status of CD43 on peripheral T cells is dynamically regulated dur-
ing a viral infection in vivo. Because PNA binding to peripheral T
cells is reduced but not abolished in the CD43/ mice, expression
of other O-glycosylated proteins such as CD8 most likely contrib-
ute to PNA binding (21–23).
Modest role for CD43 in costimulation in vivo
Cross-linking CD43 has been shown to play a role in the costimu-
lation of T cells in vitro (12); however, CD43/ T cells have been
shown to be hyperproliferative in vitro (8, 13). We examined the
CD8 T cell response on day 8 in CD43/ mice after acute infec-
tion with LCMV. Wild-type mice show the peak of expansion
approximately day 8 postinfection. While CD43/ mice show
similar percentages of virus-specific CD8 T cells (Fig. 1), the total
cell number is slightly reduced, accounting for an 1.5- to 2-fold
reduction in the numbers of virus-specific T cells in CD43/
mice (Fig. 2, A and B). Both groups of mice show undetectable
virus titers in day-8 serum, liver, kidney, and spleen (data not
shown). CTL-specific lysis was measured, as well as intracellular
cytokine production, and no differences were seen in CD43/
mice, even when data were normalized for CD8 T cell numbers
(Fig. 2C and data not shown). CD8 T cells specific to subdominant
epitopes Dbgp276–306 and KbNP205–212 were also reduced in
magnitude in CD43/ compared with CD43/ mice (Fig. 2D).
These results demonstrate a modest effect in the expansion of naive
CD8 T cells, supporting a role in costimulation. However, this
slight decrease in expansion has little overall effect on the acute
immune response, as viral clearance is unaffected.
Role for CD43 in trafficking of CD8 T cells to tissues
CD43 has been shown to play a role in the trafficking of T cells and
monocytes to sites of inflammation (10, 11). However, it is also
purported to play an antiadhesive role in lymphocyte trafficking,
suggesting increased trafficking of lymphocytes to some tissues in
FIGURE 1. Generation of Ag-specific CD8 T cells in CD43/ mice.
A, CD43/ and CD43/ mice were infected with 2  105 PFU LCMV-
Armstrong i.p., and the LCMV-specific CD8 T cell response was analyzed
on day 0 (naive), day 8 (effector), and day 65 (memory) postinfection.
Spleen cells were analyzed with DbNP396–404 MHC class I tetramer and
anti-CD8. B, Gating on CD8 T cells from uninfected mice (naive) or
DbNP396-specific CD8 T cells day 8 (effector) or day 65 (memory) postin-
fection. Binding by mAbs S7 and 1B11 was analyzed for both CD43/
and CD43/ mice. CD43/ CD8 T cells show constitutive binding by S7
and CD43/ T cells show an absence of S7 binding. DbNP396-specific
effector CD8 T cells show increased binding of 1B11 in CD43/ mice,
while this binding remains low on CD43/ CD8 T cells, demonstrating
that CD43 expression is required for 1B11 binding on effector T cells.
Double staining and gating on day 8 effector DbNP396-specific CD8 T cells
reveals binding of both S7 and 1B11 on the same cells in CD43/ mice.
C, Gating on naive phenotype (CD44low) CD8 T cells from uninfected
mice or DbNP396-specific CD8 T cells from day 8 (effector) or day 65
(memory) postinfection reveals reduced binding of PNA on CD43/ ef-
fector and memory CD8 T cells in comparison to CD43/.
Table I. Summary of mAb binding of S7 and 1B11 on naive and
activated CD4 and CD8 T cells
mAb
CD4 CD8
CD44low CD44high CD44low Effector Memory
S7 /    
1B11 /  /  
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the absence of CD43 (9). We examined the role of CD43 in traf-
ficking of CD8 T cells to the brain of i.c. infected mice. In this
model, infiltration of LCMV-specific CD8 T cells to the meninges
of i.c. infected mice results in mortality, and the onset of symptoms
leading to mortality is rapid and acute (reviewed in Ref. 24).
CD43/ or CD43/ mice were infected with 1  102 or 1  105
PFU LCMV-Armstrong i.c. and survival was examined. Although
both / and / mice demonstrated 100% mortality regardless
of the dose used, CD43/ mice showed a delay in the onset of
mortality at both high and low viral doses (Fig. 3A and data not
shown). These results suggested that, while functional, the
CD43/ CD8 T cells may be defective in their ability to traffic to
the brain.
We examined this in more detail by analyzing T cell responses
in isolated mononuclear cells from brain vs spleen at day 6 post-
challenge i.c. At this time point, while CD43/ and CD43/
mice showed similar numbers of Ag-specific CD8 T cells in the
spleen, CD43/ mice showed fewer virus-specific CD8 T cells in
isolated mononuclear cells from brain (Fig. 3B). By comparing
CD44high CD8 T cells in the spleen and the brain as a ratio, we saw
that this difference in activated CD8 T cells in the brain exceeds
the difference seen in the spleen and suggests this difference is
more than that seen from costimulation only (data not shown).
Immunohistochemistry of brain sections confirmed that CD43/
mice had reduced CD8 T cell infiltrates in the leptomeninges (Fig.
3, C and D), as well as choroid plexus and ventricular ependyma.
These results suggest that CD43 plays a significant role in the
trafficking of CD8 T cells to the CNS. Additionally, it supports
previously published work using Ab blockade of CD43 to prevent
T cell infiltration to inflamed pancreatic islets and salivary and
lacrimal glands of nonobese diabetic mice (10, 25). However, this
defect in trafficking appears to be tissue specific, as we saw no
defect in trafficking of T cells to the liver of infected CD43/
mice (as shown later). Furthermore, CD43/ mice rejected skin
allografts at days 10–13, similar to CD43/ mice, suggesting no
defect in trafficking of CD43/ T cells to skin. Thus, different
tissues may have different CD43-dependent mechanisms of T cell
migration during immune responses.
CD43 plays a negative regulatory role in the down-modulation
of the immune response
When we examined the kinetics of the immune response in
CD43/ mice we saw a modest role in the expansion phase of the
FIGURE 2. Minimal role for CD43 in generation of a primary LCMV-specific CD8 T cell response. A and B, Splenocytes from CD43/ and CD43/
mice challenged with 2  105 PFU LCMV-Armstrong were stained with DbNP396–404-specific and D
bgp33–41-specific MHC class I tetramers and the total
number of specific CD8 T cells was determined on day 8 postinfection. CD43/ showed reduced numbers, 1.5- to 2-fold compared to CD43/ (n 
7). , p  0.5; , p  0.01 (Student’s t test). C, Splenocytes were cultured with virally infected target cells for 5 h at the indicated E:T ratio and 51Cr
release was measured. Both / and / mice showed similar cytolytic killing of target cells. Similar results were obtained when data were normalized
for CD8-specific responses. D, CD8 T cell-specific responses to LCMV subdominant epitopes Dbgp276–306 and KbNP205–212 were analyzed by intra-
cellular cytokine staining on day 8 postinfection.
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response but, surprisingly, a significant delay in the down-modu-
lation or waning of the response (Fig. 4). Days 8–15 following
LCMV challenge are characterized by a precipitous loss in the
numbers of Ag-specific T cells, usually resulting in an 10-fold
reduction of Ag-specific T cells (26, 27). On day 15 postinfection,
CD43/ mice showed consistently higher numbers of activated
CD8 T cells, demonstrating only an 2-fold reduction in Ag-spe-
cific T cells, suggesting a defect in the death or increased prolif-
eration of these cells (Fig. 4).
This delay in the down-modulation of the response is not spe-
cific to viral responses, because we observe this in allospecific
responses as well. In skin allograft responses, the peak of the al-
lospecific T cell response is around day 12 and wanes by day 16
(28). When CD43/ mice were given an allogeneic skin graft
(H-2d), they rejected the graft with similar kinetics to CD43/,
approximately days 10–13 postgraft (Fig. 5). However, they had
slightly reduced numbers of allospecific T cell responses (1.7-fold)
at the peak of the response (day 12), showing that, similar to the
viral infection data, there is a modest effect on the generation of the
T cell response (Fig. 5). During the contraction phase, by day 16,
CD43/ mice showed increased allospecific T cell numbers rel-
ative to wild-type mice (Fig. 5). Taken together with the acute
LCMV response, the absence of CD43 resulted in a delay in the
waning or contraction of the T cell response, resulting in longer
persistence of Ag-specific T cells in vivo.
Increased numbers of activated T cells not due to increased
proliferation
To determine whether this increase in numbers of activated T cells
during the contraction phase was due to increased proliferation of
/ T cells, CD43/ or CD43/ mice were infected with
LCMV-Armstrong, and on days 8–15 postinfection they were
given BrdU in their drinking water. On day 15 postinfection, mice
were sacrificed and BrdU incorporation was examined in CD8 T
cells from the spleen, liver, and PBMC. CD43/ virus-specific
CD8 T cells showed no increased BrdU incorporation in any of the
tissue compartments examined, suggesting no increased prolifer-
ation during the contraction phase, even though increased numbers
of Ag-specific CD8 T cells were observed (Fig. 6). These data
FIGURE 3. Role for CD43 in trafficking of CD8 T cells to CNS. A, Mice were infected with 100 PFU Armstrong i.c. and the percentage of survival
was measured. CD43/ mice showed increased survival time relative to CD43/ mice of 24–36 h, even at higher infection doses (data not shown).
While death is delayed, all CD43/ mice eventually succumb to disease. B, On day 6 postinfection i.c., CD8 T cell responses were analyzed by flow
cytometry in splenocytes and CNS mononuclear cells. While similar responses were seen in the spleen at this time, CD43/ mice showed reduced
Ag-specific CD8 T cells in CNS mononuclear cells by flow cytometry. The upper number indicates the percentage of total Ag-specific cells; the lower
number in parentheses indicates the percentage of CD8 T cells. C and D, Photomicrographs of sagittal brain sections from mice at 6 days postinfection
showing CD8 T cell infiltrates in the meninges of CD43/ mice (C) vs CD43/ mice (D). Scale bar  100 m. Uninfected mice showed few CD8
T cells in both CD43/ and CD43/ mice (data not shown).
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argue against increased proliferation of CD43/ CD8 T cells dur-
ing the contraction phase. However, the defect in the contraction
phase is not permanent, as immune mice at days 50 and 65 show
similar numbers of Ag-specific CD8 T cells (Fig. 4). Rather, it is
a transient defect or delay.
Increased Bcl-2 expression and decreased apoptosis of virus-
specific / CD8 T cells
We examined whether this delay in the contraction phase was due
to decreased death, because we saw no evidence of increased pro-
liferation. We examined bcl-2 levels in Ag-specific effector CD8 T
cells from CD43/ mice. Bcl-2 has been characterized as an an-
tiapoptotic protein and its overexpression has been found to in-
crease resistance to apoptosis (29). Following viral infection, bcl-2
FIGURE 4. Kinetics of Dbgp33-specific and DbNP396-specific CD8 T
cell responses in CD43/ vs CD43/ mice suggest a role for CD43 in
down-modulation of immune response. Mice were infected with 2  105
LCMV-Armstrong i.p. and at days 5, 8, 15, 50, and 65 postinfection, and
virus-specific splenic CD8 T cells were quantitated by MHC class I tet-
ramers DbNP396 (A) or D
bgp33 (B). The expansion of virus-specific CD8 T
cells was slightly reduced in CD43/ mice. However, during the contrac-
tion phase (days 8–15), the decline or loss of virus-specific CD8 T cell
numbers is delayed in CD43/ relative to CD43/ mice (, p  0.5; ,
p  0.01). While the fold decrease in CD43/ mice during days 8–15 is
10-fold, the fold decrease in CD43/ mice is 2-fold. Both CD43/
and CD43/ mice showed similar virus-specific CD8 T cells in the mem-
ory pool on days 50 and 65, suggesting that this is a transient defect. On
day 15 postinfection CD43/ mice show increased percentages (C) and
numbers (D) of activated phenotype CD8 T cells (CD62Llow) compared to
CD43/ mice (p  0.01). Each symbol represents one mouse with a
minimum of n  3 for each genotype at each time point.
FIGURE 5. Defective down-modulation in allospecific responses. A,
CD43/ mice (E) and CD43/ mice (f) received H-2d skin allografts
and skin graft survival was measured. Both CD43/ and CD43/ mice
rejected grafts with similar kinetics between days 10 and 13. On days 12
(B) and 16 (C) after receiving grafts, allospecific responses were measured
by IFN- ELISPOT assay. CD43/ mice show slightly decreased num-
bers of allospecific responses in the PBMC on day 12 after graft, the peak
of the response in wild-type mice (1.5- to 2-fold). B, During the waning of
the response on day 16, CD43/ mice show increased numbers of al-
lospecific splenic T cells compared to CD43/. Data from one of two
similar experiments using / (n  5) and / (n  5) are shown.
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expression has been found to decrease on effector cells compared
with naive T cells and then increase again on memory T cells to
higher levels than on naive (27, 30). CD43/ effector virus-spe-
cific T cells showed increased levels of bcl-2 compared with
CD43/ (Fig. 7). However, directly ex vivo, we saw similar per-
centages (3–6%) of apoptotic Ag-specific CD8 T cells by Annexin
V and 7-AAD at day 8, 10, or 12 (data not shown). Because ap-
optotic cell uptake is very efficient in vivo, we examined death of
effector Ag-specific CD8 T cells from / or / mice after in
vitro culture. Culturing of an equal number of spleen cells over-
night revealed 2- to 3-fold increased percentages of Annexin V7-
AAD cells in / vs / effector CD8 T cells (Fig. 7). Taken
together with our results showing no increased BrdU incorporation
of / CD8 T cells, these results suggest that the increased
numbers of Ag-specific CD8 T cells during the contraction
phase of an immune response in CD43/ mice is most likely
the result of a defect in apoptosis of effector CD8 T cells. These
data would support studies suggesting a role for CD43 in apo-
ptosis of leukocytes (31, 32).
Chronic infection results in increased mortality in
CD43/ mice
We examined chronic infection in CD43/ vs CD43/ mice
using a persistent strain of LCMV, clone 13. Because the virus is
not cytopathic, LCMV is a classic model of immunopathology.
Tissue damage that occurs following infection is entirely depen-
dent on the immune response (reviewed in Ref. 24). Previous re-
ports have suggested that functional inactivation or down-modu-
lation of immune responses during chronic infection are critical for
host survival (33–35). When previously uninfected adult mice are
infected with LCMV clone 13 i.v., the virus replicates and dis-
seminates rapidly (36). It can persist in the serum for up to 100
days, and remains indefinitely in some tissues. When CD43/
mice were infected with LCMV clone 13 they showed similar
FIGURE 6. Increased numbers of activated CD8 T cells in CD43/ mice during the contraction phase is not due to increased proliferation. A, Mice
were infected with 2  105 PFU LCMV-Armstrong and given 1 mg/ml BrdU in drinking water for days 0–8 (control) or days 8–15 (CD43/ or
CD43/). Ag-specific responses were analyzed in lymphocytes from spleen, liver, and PBMC, and BrdU incorporation was measured. Analysis of a
representative animal is shown. Analysis of CD43/ animals revealed no increased BrdU incorporation relative to CD43/, suggesting no increased
proliferation of Ag-specific CD8 T cell on days 8–15. B, DbNP396-specific CD8 T cell responses in the spleen, liver, and PBMCs of CD43
/ and CD43/
mice show increased numbers on day 15 in each compartment analyzed in CD43/ mice (n  3).
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Ag-specific responses in spleen, liver, and PBMC compartments at
day 8 (Fig. 8A). Furthermore, day 8 postinfection viral titers in the
serum of / and / mice are comparable (Fig. 8B). However,
CD43/ mice showed dramatically increased disease following
day 7 postinfection and increased mortality relative to wild-type
mice (Fig. 8C). Together with the data from acute infection show-
ing persistence of activated CD8 T cells during the contraction
phase in vivo, these data support a negative regulatory role of
CD43 on activated CD8 T cells. During chronic viral infection,
CD43 appears to play a critical negative regulatory role during
down-modulation, and in its absence immunopathology may re-
sult, causing increased mortality. These results argue for a very
dynamic role of the CD43 glycoprotein during an immune response
reflective of the dynamic modification through the expression and
glycosylation it undergoes during an immune response. On naive T
cells it may play a more positive regulatory role in costimulation and
trafficking, while on effector T cells it may play a more negative
regulatory role in mediating the death of effector T cells.
Discussion
Putative mechanisms underlying positive and negative
regulatory roles of CD43
The exact role of CD43 has not been well defined, due to its seem-
ingly contradictory roles in several processes such as cell adhesion
and costimulation. We propose that, depending on the state of acti-
vation of the T cell, CD43 may have positive or negative regulatory
roles during an immune response. On a naive T cell, the 115-kDa
glycoform is abundantly sialylated, and this large negatively charged
glycoprotein seems to play a negative regulatory role in T cell homing
(9) and activation in vitro (8). However, our work suggests that, on
activated T cells, CD43 and other cell surface glycoproteins become
hyposialylated. This reduction in sialic acid content could result in
reduced binding to endogenous lectins such as the recently described
CD43 counterreceptor Siglec-1 (37), a sialic acid-binding lectin, and
enhanced binding to lectins such as MMGL (38) and galectin-1 (39)
that recognize terminal galactose residues on cell surface glycopro-
teins. Thus, depending on the type of ligand/receptor interactions
FIGURE 7. Increased Bcl-2 levels and decreased death of Ag-specific
CD8 T cells from CD43/ mice. A, Virus-specific CD8 T cells from
CD43/ mice (thick line) and CD43/ mice (thin line) were assayed for
Bcl-2 levels ex vivo by FACS on day 10. DbNP396–404-specific effector CD8
T cells from CD43/ mice show reduced Bcl-2 levels relative to naive
CD44low CD8 T cells (dotted line), as previously shown. CD43/ Ag-specific
CD8 T cells show higher levels of Bcl-2 compared to CD43/. B, Spleno-
cytes from LCMV-infected (day 12) CD43/ and CD43/ were cultured
overnight and apoptotic cells were assayed by 7-AAD and Annexin V staining.
Analysis of virus-specific CD8 T cells revealed decreased percentages of
7-AADAnnexin V cells in CD43/ mice compared to CD43/. Similar
results were seen from cultures on days 8 and 10.
FIGURE 8. Increased mortality following chronic LCMV infection. A,
CD43/ and CD43/ mice were infected with LCMV clone 13, which
causes chronic infection. On day 8, spleen, liver, and PBMCs were har-
vested, and similar Ag-specific responses were seen. B, LCMV virus titer
on day 8 postchallenge in the serum was measured by plaque assay and
CD43/ and CD43/ mice showed similar viral loads (n  10). The
dashed line represents the limit of detection for this assay. C, After infec-
tion with LCMV clone 13, CD43/ mice show more disease by day 7 and
become moribund beginning on day 8 postinfection. In three experiments,
survival was 10 of 10 for / and 0 of 10 for /.
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being studied, differential glycosylation of CD43 could control the
type or magnitude of specific T cell interactions.
Interestingly, CD43 expression as assayed by S7 binding is dif-
ferentially regulated on CD4 vs CD8 T cells. CD8 T cells show
constitutive S7 binding on both CD44high and CD44low CD8 T
cells, while CD4 T cells show S7 binding on CD44high but not
CD44low T cells (40). However, CD4 T cells and CD8 T cells
show increased binding of 1B11 on CD44high cells. This differen-
tial expression of CD43 may play a role in differential activation
and clearance rates of CD8 T cells and CD4 T cells (41).
Our finding showing no increase in 1B11 binding of CD43/
effector CD8 T cells in vivo extends previous work noting low-
level binding to thymocytes and Con A blasts of CD43/ mice
(7). This group saw 1B11 reactivity in CD43/ mice on a subset
of lymph node cells and noted low-level binding to a small pop-
ulation of CD8 splenocytes in CD43/ mice as data not shown.
They suggested this 1B11 reactivity was binding an epitope on
CD45RB that is independent of core 2 O-glycans. Importantly,
they clearly state this binding on blasts and thymocytes is much
less than 1B11 binding on wild-type cells, which agrees with our
work on Ag-specific CD8 T cells. Our data show clearly that on
virus-specific effector and memory CD8 T cells generated after an
in vivo challenge the up-regulated binding of 1B11 is dependent
on CD43 expression.
Mortality in mice following LCMV infection i.c. has been
shown to be critically dependent on functional CD8 T cell infil-
tration of the brain (reviewed in Ref. 24). We show that CD43/
mice infected with LCMV-Armstrong i.c. show a delay in mortal-
ity, and this delay is consistent with our findings showing reduced
numbers of CD8 T cell infiltrates in the CNS of these mice. These
results are suggestive of a defect in CD8 T cell trafficking to the
CNS, but they do not rule out alternative mechanisms. One report
examining CD43 expression in brain tissue of normal and Alzhei-
mer’s disease cases demonstrated the expression of CD43 on hu-
man microglia (42). It is possible that the reduction in CD8 T cell
numbers in the CNS of CD43/ mice could be secondary to a
defect in microglial cells. Thus, the contribution of other cell types
to the defect seen in these mice remains to be determined.
Recent cross-linking studies have suggested that T cell activa-
tion through CD43 leads to vav tyrosine phosphorylation and in-
duces Cbl-serine phosphorylation (4, 43). Cbl and cbl-b have been
shown to negatively regulate T cell activation (44–46). Interest-
ingly, Wiskott-Aldrich syndrome protein (WASp) is purported to
be a downstream signaling target of the cbl-b signaling cascade
(44). CD43 was earlier characterized because of its disrupted ex-
pression/glycosylation on leukocytes from patients suffering from
the X-linked immunodeficiency Wiskott-Aldrich syndrome (47,
48). It has been demonstrated that mutation(s) in WASp is the
causative mutation for this disease (49). T cells from WASp/
mice fail to form effective TCR caps, resulting in defects in sig-
naling through the TCR (50). Recent work has shown that CD43
is excluded from the TCR-APC synapse and that this movement of
CD43 away from the synapse is mediated by ezrin-radixin-moesin-
dependent mechanisms (14–17). Thus, the disregulation of CD43
in patients with Wiskott-Aldrich syndrome may serve as some sort
of compensatory mechanism in T cell activation in these patients
due to cytoskeleton considerations. Future studies will aim at ex-
amining TCR signaling in Ag-specific effector and memory
CD43/ and CD43/ CD8 T cells.
Finally, it is interesting to note that the high-molecular mass
glycoform of CD43 remains high on T cells during chronic infec-
tion in both mice (T. Onami and R. Ahmed, unpublished data) and
humans (51). During the course of an acute infection, CD43 on
activated T cells seems to serve to regulate the numbers of acti-
vated T cells that remain during the waning of the response. Per-
haps during a chronic infection CD43 may serve to regulate num-
bers and/or responsiveness of the T cell to persisting Ag. Future
studies will examine these questions in more detail.
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